Skip to main content

Table 5 Univariate and multivariate analysis of potential prognostic factors

From: Prevalent distribution and survival outcome of HPV infection in patients with early-stage cervical cancer in Hangzhou, China

Characteristic/Variable

N (%)

5-year OS(%)

Univariate Analysis

Multivariate Analysis

P value

P value

HR (95% CI)

Age (years)

  

0.846

 ≤ 48

795 (55.8)

90.9

   

 > 48

630 (44.2)

91.3

   

FIGO stage

  

0.013

0.214

 IA1–IB2

903 (63.4)

92.5

   

 IIA1–IIA2

522 (36.6)

88.7

   

SCC-Ag (ng/ml)

  

0.000

0.112

-

 < 1.5

608 (42.7)

94.7

   

 ≥ 1.5

817 (57.3)

88.4

   

Histological grade

  

0.039

0.576

-

 G1

199 (14.0)

95.0

   

 G2–G3

1226 (86.0)

90.5

   

Deep stromal invasion

  

0.000

0.007

1.89 (1.19–2.99)

 Superficial (< 1/2)

586 (41.1)

95.6

   

 Deep (≥ 1/2)

839 (58.9)

88.0

   

LVSI

  

0.000

0.023

1.63 (1.07–2.48)

 Negative

681 (47.8)

94.9

   

 Positive

744 (52.2)

87.6

   

Para-aortic/Pelvic LN

  

0.000

0.000

2.56 (1.74–3.75)

 Negative

1174 (82.4)

93.7

   

 Positive

251 (17.6)

78.9

   

Routes of surgery

     

 Open

1315 (92.3)

90.9

0.344

 Laparoscopic

110 (7.7)

93.6

   

Post-operative therapy

  

0.001

0.684

 None

523 (36.7)

94.1

   

 Yes

902 (63.3)

89.1

   

HR-HPV status

  

0.243

 Negative

247 (17.4)

89.1

   

 Positive

1178 (82.6)

91.5

   

HR-HPV pattern

  

0.474

 Single

998 (70.0)

91.4

   

 Multiple

180 (12.6)

92.2

   

HPV16 status

  

0.057

 Negative

429 (30.0)

89.1

   

 Positive

929 (70.0)

92.1

   

HPV58 status

  

0.505

 Negative

1301 (91.3)

91.2

   

 Positive

124 (8.7)

89.5

   

HPV18 status

     

 Negative

1316 (92.7)

91.3

0.225

 Positive

109 (7.7)

88.1

   

HPV52 status

     

 Negative

1361 (95.5)

91.0

0.768

 Positive

64 (4.5)

92.2

   

Total cases

1425

91.1

   
  1. FIGO International Federation of Gynecology and Obstetrics, HR-HPV high risk human papillomavirus, LN lymph node, LVSI lymph-vascular space invasion, OS overall survival, SCC-Ag serum squamous cell carcinoma antigen